Your browser doesn't support javascript.
loading
Clinical efficacy of tumor organoid-guided cancer therapy for locally advanced unresectable or metastatic breast cancer.
Lin, Ying-Yi; Gao, Hong-Fei; Li, Hong; Hu, Qiong; Du, Bo-le; Li, Sheng; Xu, Fang-Ping; Cheng, Min-Yi; Zou, Jia-Chen; Zheng, Xing-Xing; Zhu, Teng; Wang, Kun.
Afiliación
  • Lin YY; Shantou University Medical College, Shantou, Guangdong, China.
  • Gao HF; Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China.
  • Li H; Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China.
  • Hu Q; Biomedical Laboratory, Jingke BioTech Group, Guangzhou, Guangdong, China.
  • Du BL; Biomedical Laboratory, Jingke BioTech Group, Guangzhou, Guangdong, China.
  • Li S; Biomedical Laboratory, Jingke BioTech Group, Guangzhou, Guangdong, China.
  • Xu FP; Biomedical Laboratory, Jingke BioTech Group, Guangzhou, Guangdong, China.
  • Cheng MY; Department of Pathology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China.
  • Zou JC; Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China.
  • Zheng XX; Guangzhou Medical University, Zhanjiang, Guangdong, China.
  • Zhu T; Southern Medical University, Guangzhou, Guangdong, China.
  • Wang K; Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China.
Int J Cancer ; 155(4): 697-709, 2024 Aug 15.
Article en En | MEDLINE | ID: mdl-38577882
ABSTRACT
Patient-derived organoids (PDOs) may facilitate treatment selection. This retrospective cohort study evaluated the feasibility and clinical benefit of using PDOs to guide personalized treatment in metastatic breast cancer (MBC). Patients diagnosed with MBC were recruited between January 2019 and August 2022. PDOs were established and the efficacy of customized drug panels was determined by measuring cell mortality after drug exposure. Patients receiving organoid-guided treatment (OGT) were matched 12 by nearest neighbor propensity scores with patients receiving treatment of physician's choice (TPC). The primary outcome was progression-free survival. Secondary outcomes included objective response rate and disease control rate. Targeted gene sequencing and pathway enrichment analysis were performed. Forty-six PDOs (46 of 51, 90.2%) were generated from 45 MBC patients. PDO drug screening showed an accuracy of 78.4% (95% CI 64.9%-91.9%) in predicting clinical responses. Thirty-six OGT patients were matched to 69 TPC patients. OGT was associated with prolonged median progression-free survival (11.0 months vs. 5.0 months; hazard ratio 0.53 [95% CI 0.33-0.85]; p = .01) and improved disease control (88.9% vs. 63.8%; odd ratio 4.26 [1.44-18.62]) compared with TPC. The objective response rate of both groups was similar. Pathway enrichment analysis in hormone receptor-positive, human epidermal growth factor receptor 2-negative patients demonstrated differentially modulated pathways implicated in DNA repair and transcriptional regulation in those with reduced response to capecitabine/gemcitabine, and pathways associated with cell cycle regulation in those with reduced response to palbociclib. Our study shows that PDO-based functional precision medicine is a feasible and effective strategy for MBC treatment optimization and customization.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Organoides Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Int J Cancer Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Organoides Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Int J Cancer Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos